Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
42.73
+1.19 (+2.86%)
Streaming Delayed Price
Updated: 2:35 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
November 12, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
November 07, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
November 05, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
9 Analysts Have This To Say About Legend Biotech
October 16, 2024
Via
Benzinga
Where Legend Biotech Stands With Analysts
September 27, 2024
Via
Benzinga
Peering Into Legend Biotech's Recent Short Interest
September 06, 2024
Via
Benzinga
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
August 28, 2024
Via
Benzinga
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
November 04, 2024
Newly created position to lead efforts focused on continued growth and sales
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
October 24, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
October 03, 2024
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Looking Into Legend Biotech's Recent Short Interest
August 16, 2024
Via
Benzinga
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
August 12, 2024
Via
Benzinga
The Latest Analyst Ratings For Legend Biotech
July 15, 2024
Via
Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
September 30, 2024
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by...
Via
Benzinga
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
September 27, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
September 27, 2024
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma.
Via
Investor's Business Daily
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 20, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
August 09, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
August 08, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
August 01, 2024
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its...
Via
Benzinga
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
July 26, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
July 21, 2024
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your...
Via
Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
July 20, 2024
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.
Via
Talk Markets
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
July 18, 2024
Via
Benzinga
CPI Data Sparks Rally in Biotech Stocks
July 15, 2024
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
July 10, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
July 02, 2024
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of...
Via
Benzinga
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
July 02, 2024
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis
From
Legend Biotech USA Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.